Inhaled Budesonide for Altitude Illness Prevention

Learn more about:
Related Clinical Trial
Effect of Acetazolamide on Sleep Disordered Breathing in Lowlanders Older Than 40 Years at Altitude Effects of Melatonin on Sleep, Ventilatory Control and Cognition at Altitude. Effect of Acetazolamide on Lung Water Content by Ultrasound in Lowlanders Older Than 40 Years at Altitude Effect of Acetazolamide on Right Heart Function During Exercise in Lowlanders Older Than 40 Years at Altitude Effect of Acetazolamide on Visuo-motor Learning in Lowlanders Older Than 40 Years at Altitude Effect of Acetazolamide on Maximal Exercise Performance in Lowlanders Older Than 40 Years at Altitude Physiological Adaptations to Simulated Intermittent Altitude on Human Health and Performance Iron Status and Cardiopulmonary Physiology Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders Older Than 40 Years at Altitude. Effect of Acetazolamide on Postural Control in Lowlanders Older Than 40 Years at Altitude Monitoring of the Cerebral Tissue Oxygenation and Perfusion in the Adapting Climber During Sleep in High Altitude The Psychophysiological Effect of Simulated and Terrestrial Altitude Relationship Between Succinate Dehydrogenase Mutations and High-Altitude Illness Cardio-respiratory Responses During Hypoxic Exercise in Individuals Born Prematurely Gut-microbiota Targeted Nutritional Intervention for Gut Barrier Integrity at High Altitude AZ, MZ, and the Pulmonary System Response to Hypoxia Study of the Effects of Iron Levels on the Lungs at High Altitude Effects of Aircraft Cabin Altitude on Passenger Comfort and Discomfort Three New Ideas to Protect Special Forces From the Stress of High Altitude Breathing Training to Improve Human Performance at High Altitude Oxidative Stress in Hypobaric Hypoxia Safety Evaluation of Aminophylline and Methazolamide Decompression Tables for Diving at Altitude Chronic Mountain Sickness, Systemic Vascular Function Evaluation of the Prevention and Treatment Effects of Chinese Medicine on High Altitude Illness Inhaled Budesonide for Altitude Illness Prevention Sickness Evaluation at Altitude With Acetazolamide at Relative Doses Prevention of Altitude Illness With Non-steroidal Anti-inflammatory Study (PAINS) Spectroscopic and Diffusion Weighted Analysis of the Effects of Dexamethasone on High Altitude Cerebral Oedema (HACE) Drug Combination on Exercise Performance at High Altitude Acclimatization Mechanisms During Ascent to 7500m Prevention of Acute Mountain Sickness by Intermittent Hypoxia Sickness Evaluation at Altitude With Acetazolamide at Relative Dosages Study Looking at End Expiratory Pressure for Altitude Illness Decrease (SLEEP-AID) Can Rhodiola Crenulata Intake Improve Oxygen Saturation and Decrease the Incidence of Acute Mountain Sickness Comparison of Metoclopramide and Ibuprofen for the Treatment of Acute Mountain Sickness A Trial of Acetazolamide Versus Placebo in Preventing Mountain Sickness During Rapid Ascent Training in Hypoxia to Prevent Acute Mountain Sickness Study of Compound Danshen Dripping Pills to Treat Acute Mountain Sickness Altitude Sickness Prevention With Ibuprofen Relative to Acetazolamide and Treatment Efficacy Controlled Hyperventilation as Prophylaxis for Acute Mountain Sickness Inhaled Budesonide and Acute Mountain Sickness Altitude Sickness Prevention and Efficacy of Comparative Treatments Alternative Treatments in Acute Mountain Sickness Effect of Acetazolamide on Acute Mountain Sickness in Lowlanders Older Than 40 Years Safety and Efficacy of T89 in Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)

Brief Title

Inhaled Budesonide for Altitude Illness Prevention

Official Title

Inhaled Budesonide for Altitude Illness Prevention

Brief Summary

      A randomized, double-blinded study administering budesonide, a medication to reduce
      inflammation in the lungs, to healthy volunteers to examine effects on altitude illness
      prevention by spending 18 hours overnight at 14,000 ft elevation.
    

Detailed Description

      A randomized, double-blinded study will be conducted to validate the results of previous
      literature on the use of budesonide in the prevention of altitude sickness. It will be
      conducted using healthy participants overseen by experienced wilderness medicine and altitude
      researchers from the Altitude Research Center at University of Colorado Denver. Participants
      will be recruited from the Denver community and prescreened for eligibility via phone. 100
      participants, after consenting, will have baseline data and blood collected and will begin
      budesonide therapy 72 hours prior to being taken from Denver to Pikes Peak, where they will
      be observed at altitude for 18 hours. Patients will have the opportunity to withdraw consent
      at any time and will be monitored continuously by physician-researchers. Data collection and
      blood draws will be performed at specific time points and analyzed for efficacy of budesonide
      vs. placebo in the incidence of altitude sickness.
    

Study Phase

Phase 3

Study Type

Interventional


Primary Outcome

Changes in Inflammation


Condition

Altitude Sickness

Intervention

Budesonide

Study Arms / Comparison Groups

 Budesonide
Description:  Will participate in all study activities but will receive budesonide.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

0

Start Date

March 6, 2017

Completion Date

March 6, 2017

Primary Completion Date

March 6, 2017

Eligibility Criteria

        Inclusion Criteria:

          -  healthy, altitude naive, 21-40 years old

        Exclusion Criteria:

          -  smokers

          -  pregnancy

          -  hx of asthma

          -  current inhaled steroid use

          -  those with diseases or disorders known to be affected by hypoxia or the drugs used in
             this study such as

               -  migraine or other chronic headaches,

               -  sickle cell trait or disease, or

               -  diabetes

          -  history of significant head injury or seizures

          -  taking any medication (over-the-counter or prescription) or herbal supplements

          -  a known hypersensitivity reaction to budesonide

          -  inability to be headache-free when consuming the amount of caffeine in two six ounce
             cups of coffee or less per day

          -  exposure to high altitude above 2000m in the previous 1 month or

          -  those who have been on an airline flight over six hours (Airplane cabins are
             pressurized to an elevation that can approximate exposure to high altitude)
      

Gender

All

Ages

21 Years - 40 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Ryan Paterson, MD, DiMM, , 



Administrative Informations


NCT ID

NCT02941510

Organization ID

16-2184


Responsible Party

Sponsor

Study Sponsor

University of Colorado, Denver


Study Sponsor

Ryan Paterson, MD, DiMM, Principal Investigator, University of Colorado, Denver


Verification Date

March 2017